BMS-754807

Catalog No.S1124

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Cited by 14 Publications

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Cytotherapy, 2019, 21(6):619-630

PubMed: 30956007 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

Drug Deliv, 2018, 25(1):241-255

PubMed: 29334272 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29099049 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

1 Customer Review

Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	Ml3FT4lv[XOnIHHzd4F6			MkS4bY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCLR1[tNXIhMEmFNUCgQUAyO26PKTDhcoQhfGinIHTve45{fHKnYX2geIFz\2W2czDBb5QhMEmFNUCgQUAzOm6PKTDhcoQhVUGSSzCoTWM2OCB;IEGzcm0q	NETmRlMyQTd5OECyOC=>
IGF-Sal	NVfzfGZZT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=			NYDYPJlsUUN3ME23JI5O	MlrDNVk4PzhyMkS=
CCRF-CEM (ALL)	MonzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYjC[GJ3hjVizszN	MmPaSG1UVw>?	M2PVfmlEPTB;MT6yN\|kh\|ryP	MormNVk6QTZ{N{K=
PC3	MlnGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXL+OUDPxE1?	NV\aUXlrTE2VTx?=	Mm\6TWM2OD1yLkm2OUDPxE1?	NIjvTWUyQTl7NkK3Ni=>
JD	Mn\aS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M33FSp42KM7:TR?=	NIXURlJFVVOR	MnPKTWM2OD1yLkO5NUDPxE1?	MnTWNVk6QTZ{N{K=
DU145	M2nRV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVr+OUDPxE1?	NWHFO\|NTTE2VTx?=	NUXGNJJuUUN3ME2xMlQ3PSEQvF2=	MoHvNVk6QTZ{N{K=
KAG	NH\sPGdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NIfPcJZ,PSEQvF2=	M3vU[2ROW09?	NXvBeXlrUUN3ME2xMlY3PSEQvF2=	MV:xPVk6PjJ5Mh?=
K-562 (CML)	MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{P3UZ42KM7:TR?=	M2jOOmROW09?	M17JW2lEPTB;Mj6zNFIh\|ryP	Mn7iNVk6QTZ{N{K=
B6-P210 (Murine ALL)	NYnSZ\|FmT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3rufZ42KM7:TR?=	M{nVPWROW09?	NITDPINKSzVyPUGuNlk{KM7:TR?=	MV:xPVk6PjJ5Mh?=
LN CAP-FGC	M{fSTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHW2cnV,PSEQvF2=	NUDybWNzTE2VTx?=	M3\JRWlEPTB;MT60N\|Qh\|ryP	MXOxPVk6PjJ5Mh?=
VW	Mn\aS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWT+OUDPxE1?	MUPEUXNQ	MVjJR\|UxRTBwMEG5JO69VQ>?	NWPYe3p4OTl7OU[yO\|I>
MV411 (B Myelomonocytic)	MknIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUL+OUDPxE1?	M4f3emROW09?	NYfQN2Q{UUN3ME2wMlM{KM7:TR?=	NIXp[XcyQTl7NkK3Ni=>
MDA-PCa-2b	NWi4cYRTT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1LYUp42KM7:TR?=	MonPSG1UVw>?	MlfLTWM2OD1yLkC5PEDPxE1?	M3G1WFE6QTl4Mkey
LG	NGH4bXRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUPMdW5UhjVizszN	MYfEUXNQ	NGnxc41KSzVyPUCuNFM5KM7:TR?=	M3\J[\|E6QTl4Mkey
RS411 (B cell precursor-ALL)	NUPQeYpxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXP+OUDPxE1?	MVfEUXNQ	NEXGNXBKSzVyPUCuNVAzKM7:TR?=	NHHTfXMyQTl7NkK3Ni=>
22-r-1	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFjH[lB,PSEQvF2=	M4TDTWROW09?	NEHEbHNKSzVyPUCuNVc2KM7:TR?=	MnTtNVk6QTZ{N{K=
5838	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUD+OUDPxE1?	M{eySGROW09?	NX6zSYJ4UUN3ME2wMlA{PCEQvF2=	NI\r[oEyQTl7NkK3Ni=>
P388 (Murine)	NVP3UYNpT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHXZO3d,PSEQvF2=	M{H1R2ROW09?	NELMNI5KSzVyPUSuNlch\|ryP	NH3vVYEyQTl7NkK3Ni=>
A2780/S	NVjiNZJ2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1XsSp42KM7:TR?=	NUXSV5BYTE2VTx?=	NVj1e4NzUUN3ME2wMlEzOiEQvF2=	NYXBTmN3OTl7OU[yO\|I>
RDES	M2\0OGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3PWRp42KM7:TR?=	NYq5emtPTE2VTx?=	MWHJR\|UxRTBwMEGyJO69VQ>?	NFnMSWoyQTl7NkK3Ni=>
B6-T315I (Murine B-ALL)	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGjWTXJ,PSEQvF2=	MVLEUXNQ	M3\KPWlEPTB;Mj64N{DPxE1?	NW\mdVd4OTl7OU[yO\|I>
TOV 112D	MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3qxcp42KM7:TR?=	Mon0SG1UVw>?	NF7OdotKSzVyPUKuNVQ3KM7:TR?=	MVixPVk6PjJ5Mh?=
TC32	NGj0ZllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3fuOZ42KM7:TR?=	MYLEUXNQ	MWHJR\|UxRTBwMEC4JO69VQ>?	NX7KWnB2OTl7OU[yO\|I>
HL60 (acute myelocytic)	MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NF;JO4F,PSEQvF2=	M1r3UmROW09?	NFzWbpBKSzVyPUCuNVIh\|ryP	NFrBNmsyQTl7NkK3Ni=>
TOV 21G	Ml;4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmK1glUh\|ryP	MnTnSG1UVw>?	MXfJR\|UxRTRwMke5JO69VQ>?	MlPKNVk6QTZ{N{K=
TC71	MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{\ybp42KM7:TR?=	MlrxSG1UVw>?	MlLGTWM2OD1yLkCxOEDPxE1?	NIXKeIMyQTl7NkK3Ni=>
HPN-ALL (T-cell)	MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVroNG9[hjVizszN	M2rOeWROW09?	MX;JR\|UxRTBwNUKg{txO	MUOxPVk6PjJ5Mh?=
A2780R	MnfwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIDvVZZ,PSEQvF2=	NXfVUGxOTE2VTx?=	NFjQXYxKSzVyPUGuOVY1KM7:TR?=	NELZfYUyQTl7NkK3Ni=>
Rh1	MmXvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHfZTGh,PSEQvF2=	Ml\pSG1UVw>?	MWfJR\|UxRTBwMEK3JO69VQ>?	Mn\4NVk6QTZ{N{K=
Kasumi-1 (acute myeloid)	M4P2Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYO0Tox5hjVizszN	MoL6SG1UVw>?	Ml\oTWM2OD1yLkG2JO69VQ>?	MoPENVk6QTZ{N{K=
sk-ov-3	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYHHeVZLhjVizszN	M4PoVWROW09?	M3zkW2lEPTB;NT6xJO69VQ>?	MnHGNVk6QTZ{N{K=
ME	MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEnTRXR,PSEQvF2=	M1PNeWROW09?	MWLJR\|UxRTBwMEG1JO69VQ>?	NH36WZkyQTl7NkK3Ni=>
L1210 (Murine lymphocytic)	M3PGUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1LmbZ42KM7:TR?=	MYjEUXNQ	M{HMXGlEPTB;Mj6zPUDPxE1?	NH3iNFcyQTl7NkK3Ni=>
sw-626	NVT5UmhPT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYrGSoRQhjVizszN	MlvESG1UVw>?	MWnJR\|UxRTJwM{C2JO69VQ>?	M4DsNlE6QTl4Mkey
CTR	NIXwVWJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUf+OUDPxE1?	NF7OcmFFVVOR	M4H0bGlEPTB;MD6yOVMh\|ryP	NVHmO\|FEOTl7OU[yO\|I>
ML2 (Myelomonocytic)	MnjGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoqzglUh\|ryP	MlzySG1UVw>?	NETkWG5KSzVyPUCuNFkh\|ryP	MlTTNVk6QTZ{N{K=
ovcar-3	M2LMR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NG[1ZnR,PSEQvF2=	MlPZSG1UVw>?	M1HofWlEPTB;NTFOwG0>	NWS1Z3NGOTl7OU[yO\|I>
Rh36	M3Ple2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIDNSmJ,PSEQvF2=	MX\EUXNQ	NYThclhSUUN3ME2xMlQ{OiEQvF2=	M33DRlE6QTl4Mkey
MOLM-13 (acute myeloid)	M1jNb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHXGSFl,PSEQvF2=	MUnEUXNQ	Mo\0TWM2OD1yLkSyJO69VQ>?	NGrjZlgyQTl7NkK3Ni=>
ovcar-4	NXm1ZopRT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NX;qOZd5hjVizszN	MlvkSG1UVw>?	MYjJR\|UxRTFizszN	MmHtNVk6QTZ{N{K=
Rh41	NWriNGlqT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGDzb2J,PSEQvF2=	MknRSG1UVw>?	MnfkTWM2OD1yLkCwOUDPxE1?	MoL0NVk6QTZ{N{K=
Mutz 2 (acute myeloid)	M{LZfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MY\+OUDPxE1?	Mle2SG1UVw>?	NWm1e\|hRUUN3ME2xMlE2KM7:TR?=	M2XJ[VE6QTl4Mkey
ovcar-5	M3TaXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYGxU49qhjVizszN	NFrueoJFVVOR	Mnf0TWM2OD1yLkC1JO69VQ>?	NGTieGMyQTl7NkK3Ni=>
RD1	NHv0XpdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmLLglUh\|ryP	MkS3SG1UVw>?	MWLJR\|UxRTBwME[4JO69VQ>?	NFr2SXcyQTl7NkK3Ni=>
OCI-AML 2 (acute myeloid)	MmDFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NX\5VoJthjVizszN	NFu5cJFFVVOR	M1\CU2lEPTB;Mz6zN{DPxE1?	MVexPVk6PjJ5Mh?=
786-O	NWfIXYViT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFnVfoh,PSEQvF2=	Mkn0SG1UVw>?	MWDJR\|UxRTFwNkS3JO69VQ>?	M1;RUVE6QTl4Mkey
A673	Ml;1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWLMPWU4hjVizszN	M4\2XGROW09?	MX3JR\|UxRTBwNEC4JO69VQ>?	MnvKNVk6QTZ{N{K=
TALL-1 (T-cell)	MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4jxcZ42KM7:TR?=	NH7lUpdFVVOR	M3TnVWlEPTB;MT6yPEDPxE1?	NULlTI5JOTl7OU[yO\|I>
151-B	MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVn+OUDPxE1?	M2PoXWROW09?	NFjl[\|BKSzVyPUKuOlch\|ryP	NEeyOWoyQTl7NkK3Ni=>
PFSK-1	NEK3doRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1TxfJ42KM7:TR?=	M4nOW2ROW09?	NUPG[2RTUUN3ME2wMlE{OiEQvF2=	M2XITlE6QTl4Mkey
THP-1	MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MX7+OUDPxE1?	NYfMOFdWTE2VTx?=	MoHBTWM2OD14LkW4JO69VQ>?	NEDhOWwyQTl7NkK3Ni=>
HEK293	NXj1fGt1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHjlR2h,PSEQvF2=	MnO2SG1UVw>?	NHXuPZRKSzVyPUCuPVE2KM7:TR?=	MmCzNVk6QTZ{N{K=
DAOY	M1SwVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1izep42KM7:TR?=	NXzje40xTE2VTx?=	M2rFSmlEPTB;MT65O\|kh\|ryP	M2GxOlE6QTl4Mkey
SET2	NYPYOoxjT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2XxN542KM7:TR?=	M2HtPGROW09?	M2D5Z2lEPTB;MD6yPVgh\|ryP	NXe0fYxMOTl7OU[yO\|I>
HTB-46	NITMcJRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3PRep42KM7:TR?=	M1\XOWROW09?	Moq2TWM2OD13LkK1JO69VQ>?	NX;3copSOTl7OU[yO\|I>
SK-NAS	M1HGdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkS2glUh\|ryP	NGS1WZVFVVOR	MnrCTWM2OD1yLkS5O{DPxE1?	NVqwWVM6OTl7OU[yO\|I>
CTLL2	NVnWfVZyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MoThglUh\|ryP	NEK0bJJFVVOR	NYLvOpV3UUN3ME6xMlAxKM7:TR?=	MY[xPVk6PjJ5Mh?=
HTB-47	MonVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFrlRY9,PSEQvF2=	NX7nW2w4TE2VTx?=	MkT0TWM2OD1{LkC1OkDPxE1?	MkHONVk6QTZ{N{K=
LAN-1	Ml7oS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVjNeIxOhjVizszN	M3fldmROW09?	NYP4NlRtUUN3ME2wMlA1KM7:TR?=	MWixPVk6PjJ5Mh?=
ST486	MknkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFjCPHd,PSEQvF2=	NV3qUGRFTE2VTx?=	NFjDc3dKSzVyPUGuNVkh\|ryP	MVqxPVk6PjJ5Mh?=
HS766T	NG\yW\|ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{\MdZ42KM7:TR?=	M3XJPWROW09?	NEHTeFFKSzVyPUKuNFAyKM7:TR?=	MoXiNVk6QTZ{N{K=
IMR-32	M3TOb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnX0glUh\|ryP	NUf1fVV7TE2VTx?=	NYDGZZJHUUN3ME2wMlI3OSEQvF2=	NWPuNoR6OTl7OU[yO\|I>
Daudi (Burkitt's)	M2CzWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUf+OUDPxE1?	MVfEUXNQ	M1:0eGlEPTB;Mj62N\|ch\|ryP	MWexPVk6PjJ5Mh?=
Aspc-1	MmLrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmToglUh\|ryP	NH70TlhFVVOR	Ml7xTWM2OD1yLkO3PUDPxE1?	MVSxPVk6PjJ5Mh?=
SK-NSH	NULseZVIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHXBZot,PSEQvF2=	NXrmUmN1TE2VTx?=	M1LhbmlEPTB;MD6xN\|kh\|ryP	M2rjU\|E6QTl4Mkey
MEC-1 (Chronic B cell)	NXXlfXl5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M17oSJ42KM7:TR?=	NUnuNFFsTE2VTx?=	M3TB[GlEPTB;Mj62N\|ch\|ryP	MoG2NVk6QTZ{N{K=
Capan-2	Ml62S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NELVUIN,PSEQvF2=	MYrEUXNQ	NWnj[5I2UUN3ME2xMlc4PCEQvF2=	MWexPVk6PjJ5Mh?=
SHSY5Y	NEnye5BIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M17lTJ42KM7:TR?=	NXTFRotWTE2VTx?=	NI\HUlFKSzVyPUCuNVA3KM7:TR?=	Ml33NVk6QTZ{N{K=
U937 (Histioocytic)	MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVm2e3FqhjVizszN	MUHEUXNQ	MVXJR\|UxRjVwMECg{txO	NEHwTmEyQTl7NkK3Ni=>
Bxpc-1	NFz2S2ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1r4[p42KM7:TR?=	NHzUWlFFVVOR	NXzDO4JmUUN3ME2xMlkzPCEQvF2=	NHnZeWkyQTl7NkK3Ni=>
Bxpc-3	NY[wbHRHT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVT+OUDPxE1?	NULWTpFxTE2VTx?=	NFflRY9KSzVyPkWuNFAh\|ryP	NXLs[4prOTl7OU[yO\|I>
HTB-92	NH\I[pBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Ml2xglUh\|ryP	Mn3vSG1UVw>?	M{PqfmlEPTB;MT6wNkDPxE1?	NVfXNYZsOTl7OU[yO\|I>
OCI-LY10 (B-cell)	NFLwXIdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NG\pZWp,PSEQvF2=	Mm\wSG1UVw>?	NWPXeYhUUUN3ME2wMlQ2KM7:TR?=	NGLZWZEyQTl7NkK3Ni=>
PANC-1	MnvKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M{Tu[J42KM7:TR?=	NUPjRWRmTE2VTx?=	MlfQTWM2OD53LkCwJO69VQ>?	M3vQ[FE6QTl4Mkey
To184.T	NYK0XVhFT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M{P0Up42KM7:TR?=	Ml7ESG1UVw>?	NWLvcph1UUN3ME2wMlQ3QSEQvF2=	NXrXepRmOTl7OU[yO\|I>
OCI-LY19 (B-cell)	NHLm[2dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NI\4V4N,PSEQvF2=	MoTrSG1UVw>?	MWHJR\|UxRTBwNDFOwG0>	Mo\SNVk6QTZ{N{K=
PANC-1 BM	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2q3UZ42KM7:TR?=	MX7EUXNQ	MYPJR\|UxRjVwMECg{txO	MYexPVk6PjJ5Mh?=
SA-4	NELabo5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUD+OUDPxE1?	NETWd\|dFVVOR	MnzWTWM2OD1zLkOwNUDPxE1?	MV2xPVk6PjJ5Mh?=
RPMI 8226	M3nMRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlviglUh\|ryP	MUTEUXNQ	NVfJ[oR2UUN3ME2xMlI6OyEQvF2=	MUixPVk6PjJ5Mh?=
HPAF-II	M4rnUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2LF[p42KM7:TR?=	NHTzfWNFVVOR	MVvJR\|UxRTBwNkS0JO69VQ>?	M1zEU\|E6QTl4Mkey
SHP-77	MUXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoK5glUh\|ryP	MnzYSG1UVw>?	NXjUTGtuUUN3ME2xMlg5QCEQvF2=	MWSxPVk6PjJ5Mh?=
U266 B1	MmnvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHjsT2J,PSEQvF2=	Mni4SG1UVw>?	NVPGcoNDUUN3ME2xMlY3QSEQvF2=	NXnkUXd4OTl7OU[yO\|I>
Hs700t	M{XjZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHPFV4F,PSEQvF2=	MofMSG1UVw>?	NFTOT5ZKSzVyPUCuNlMyKM7:TR?=	NHz0SXYyQTl7NkK3Ni=>
NCI-446	NYPoeZhGT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2X6Up42KM7:TR?=	MX\EUXNQ	M2DTT2lEPTB;MT6xOVQh\|ryP	MXKxPVk6PjJ5Mh?=
H929	M4T0emdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHTrb2d,PSEQvF2=	MkD6SG1UVw>?	NIPvRmxKSzVyPUCuNFE1KM7:TR?=	NILRN2syQTl7NkK3Ni=>
PL45	NUjifoFHT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX3+OUDPxE1?	NGHX[GhFVVOR	M2DHdmlEPTB;Mj6yOVUh\|ryP	NVnSZWFROTl7OU[yO\|I>
NCI-H383	NG\z[nJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGTlSHV,PSEQvF2=	M4rUN2ROW09?	MnXyTWM2OD53LkCwJO69VQ>?	MWixPVk6PjJ5Mh?=
JJN3	NYe5RYFXT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVK4OoFXhjVizszN	MkPvSG1UVw>?	M4DlZWlEPTB;Mj60N\|Mh\|ryP	NVjWNXpmOTl7OU[yO\|I>
SU.86.86	NGHaNnpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlO1glUh\|ryP	M2n2XGROW09?	MU\JR\|UxRTJwNkeyJO69VQ>?	NHXxTlkyQTl7NkK3Ni=>
H1299	NEDRfWVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHTY[Gp,PSEQvF2=	MkTBSG1UVw>?	MWLJR\|UxRjVwMECg{txO	M3npXlE6QTl4Mkey
MDA-MB-468	NVnvPXh3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NInKNXJ,PSEQvF2=	MlmxSG1UVw>?	M3PRXmlEPTB;MD61NFQh\|ryP	MlPsNVk6QTZ{N{K=
SW1990	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIDGNm5,PSEQvF2=	MkK0SG1UVw>?	MUPJR\|UxRTBwOEK2JO69VQ>?	NUnvVXE{OTl7OU[yO\|I>
Calu-6	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXz+OUDPxE1?	NYTnfpZoTE2VTx?=	NYfv[HVRUUN3ME61MlAxKM7:TR?=	M3nEflE6QTl4Mkey
MDA-MB-231	NWDHPXBVT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFW1e4l,PSEQvF2=	NYm0cW5jTE2VTx?=	M{HySGlEPTB;MT62OFgh\|ryP	MVixPVk6PjJ5Mh?=
SW-684	MmO4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX3+OUDPxE1?	Mk\XSG1UVw>?	M3K5d2lEPTB-NT6wNEDPxE1?	NFHKXWcyQTl7NkK3Ni=>
H209	NXGzc4NKT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGrLcJR,PSEQvF2=	NWjNWpFrTE2VTx?=	NWS1XlNWUUN3ME2xMlE6OyEQvF2=	NYjuO\|FKOTl7OU[yO\|I>
MDA-MB-231T	MmjKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1z1V542KM7:TR?=	NFf2ephFVVOR	M4f6WWlEPTB-NT6wNEDPxE1?	NGnTXmYyQTl7NkK3Ni=>
HT1080/S	NIG5d4RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MonRglUh\|ryP	NUiwbng3TE2VTx?=	MonkTWM2OD1yLkWzNUDPxE1?	NWTLNIRjOTl7OU[yO\|I>
H526 0.044	M3X5VGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWrZfW1QhjVizszN	NF;JdWlFVVOR	MVPJR\|UxRTBwMES0JO69VQ>?	M1zDUFE6QTl4Mkey
DU4475 2.431	MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mli5glUh\|ryP	MmfkSG1UVw>?	NEn6T2FKSzVyPUKuOFMyKM7:TR?=	MV[xPVk6PjJ5Mh?=
HCT116	NWP4[Y96T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFi4O2N,PSEQvF2=	NFrNSXpFVVOR	NGXjdVZKSzVyPUCuPFUzKM7:TR?=	NULXZVVtOTl7OU[yO\|I>
M109	MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mo\DglUh\|ryP	MV7EUXNQ	M1PLWWlEPTB;MT6wOVUh\|ryP	NFHvXmkyQTl7NkK3Ni=>
BT549	MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYjZNoFnhjVizszN	M3\JcGROW09?	MX;JR\|UxRTFwNkS1JO69VQ>?	NYrQNlAxOTl7OU[yO\|I>
HCT116/VM46	MmnoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3ixN542KM7:TR?=	NF7jSYxFVVOR	NEK4XWdKSzVyPUGuO\|AzKM7:TR?=	MVKxPVk6PjJ5Mh?=
H460	Ml7kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVT+OUDPxE1?	MXfEUXNQ	Mo\CTWM2OD1yLke5OUDPxE1?	NFTsPXEyQTl7NkK3Ni=>
MCF-7	NUXZXZh5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NULEVGMyhjVizszN	M2roOGROW09?	M2L6PWlEPTB;MD6wNVYh\|ryP	MVixPVk6PjJ5Mh?=
GEO	NEC2PJRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVT+OUDPxE1?	NYr4O4ZOTE2VTx?=	MkT0TWM2OD1yLkO1OkDPxE1?	NH\ycWQyQTl7NkK3Ni=>
H441 0.646	MnrvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVn+OUDPxE1?	MUXEUXNQ	NYi4U4JIUUN3ME2wMlY1PiEQvF2=	NELhVmYyQTl7NkK3Ni=>
MCF-7-807R	M{jSU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NW\xdI1phjVizszN	NHzrbZdFVVOR	NWjmOml5UUN3ME2wMlQ6KM7:TR?=	M3Lld\|E6QTl4Mkey
Colo205	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXrYdJM{hjVizszN	NVjQdHdpTE2VTx?=	NXrsZpJRUUN3ME2wMlExPCEQvF2=	NIXLbnEyQTl7NkK3Ni=>
H292	Ml3LS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmT2glUh\|ryP	NH[1eoFFVVOR	MX\JR\|UxRTBwN{i4JO69VQ>?	NVnqVFdqOTl7OU[yO\|I>
BT474 (S)	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIrIS5B,PSEQvF2=	MWTEUXNQ	NV73d4F7UUN3ME2yMlQxOyEQvF2=	M1nOc\|E6QTl4Mkey
HT-29	MmLnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnTTglUh\|ryP	MlLySG1UVw>?	MY\JR\|UxRTJwMUCzJO69VQ>?	M2DEOVE6QTl4Mkey
A549	NY\lOlBnT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MoX5glUh\|ryP	NWPFSHBlTE2VTx?=	NUD0cY9VUUN3ME2wMlY4PSEQvF2=	MVWxPVk6PjJ5Mh?=
BT474-M1	M1j3bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXnJengyhjVizszN	M3KwWmROW09?	M3j4RWlEPTB;Mj6zOlUh\|ryP	NV;icGdUOTl7OU[yO\|I>
SW480	NIf3epRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3LVbJ42KM7:TR?=	M3G4S2ROW09?	MUDJR\|UxRjVwMECg{txO	MoPYNVk6QTZ{N{K=
L2987	MoPyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXv+OUDPxE1?	NY\XO3ZwTE2VTx?=	NHzweXpKSzVyPUCuOFQzKM7:TR?=	M{f3flE6QTl4Mkey
AU565	NXzNWlZyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUn+OUDPxE1?	M3PXbWROW09?	M{XHW2lEPTB;ND65O{DPxE1?	M4DPcVE6QTl4Mkey
SW403	NUPReGZFT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkPiglUh\|ryP	MlXxSG1UVw>?	MXXJR\|UxRTBwMkKg{txO	MmW5NVk6QTZ{N{K=
H1437	MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXX+OUDPxE1?	Mo\HSG1UVw>?	MoXxTWM2OD1yLkWyN{DPxE1?	NF2ybnMyQTl7NkK3Ni=>
BT-20	NXXsV\|huT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYP+OUDPxE1?	NULDdXU1TE2VTx?=	M176[2lEPTB;Mz61OlIh\|ryP	NYK5ZVlxOTl7OU[yO\|I>
Colo320HSR	MmDYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFn2PZN,PSEQvF2=	M1;4XWROW09?	M{jCOWlEPTB;MD6wNVEh\|ryP	MVKxPVk6PjJ5Mh?=
H2087	NEHDWIxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGHWTI9,PSEQvF2=	NXHUWHdUTE2VTx?=	MXnJR\|UxRjFwMECg{txO	M{jQflE6QTl4Mkey
HCC1419	NUnDNHV5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MlnTglUh\|ryP	NXPFXnFlTE2VTx?=	NHfDd3lKSzVyPUKuOVE4KM7:TR?=	MX2xPVk6PjJ5Mh?=
WiDr	M2iwdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M13rWp42KM7:TR?=	Mk[5SG1UVw>?	M3\I[GlEPTB;MD6wO\|Yh\|ryP	M4jZRVE6QTl4Mkey
H661 0.573	NXvVXItST3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEHZ[JB,PSEQvF2=	Mon4SG1UVw>?	MUfJR\|UxRTBwNUezJO69VQ>?	MWCxPVk6PjJ5Mh?=
HCC-38	MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{C5dp42KM7:TR?=	MYjEUXNQ	MX\JR\|UxRjVwMECg{txO	MXGxPVk6PjJ5Mh?=
LS174T	NWPFOmpOT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M33sZ542KM7:TR?=	NVzZWFhrTE2VTx?=	MYHJR\|UxRTBwNUO1JO69VQ>?	MoD2NVk6QTZ{N{K=
H211	MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NX3tOXI{hjVizszN	MYnEUXNQ	MlvyTWM2OD1yLkezN{DPxE1?	NXrwcXNVOTl7OU[yO\|I>
HCC70	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4mwN542KM7:TR?=	NGLBPHRFVVOR	MYLJR\|UxRTFwNUWg{txO	NYTXdFFxOTl7OU[yO\|I>
SW116	NVPNcpE4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1XpVZ42KM7:TR?=	NFzZeVBFVVOR	MYTJR\|UxRTBwME[3JO69VQ>?	MoXVNVk6QTZ{N{K=
H513	M4iyTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3uyUJ42KM7:TR?=	NIjtV3dFVVOR	NYrHVnVqUUN3ME20MlQ1QCEQvF2=	MV[xPVk6PjJ5Mh?=
MDA-MB-157	NYDvWVVMT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXPpenNFhjVizszN	MV;EUXNQ	M3XKc2lEPTB;MD6wN\|Yh\|ryP	MmnkNVk6QTZ{N{K=
H2052	M{fRWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUH+OUDPxE1?	NGnXOXVFVVOR	NUSxe2lOUUN3ME2xMlA2KM7:TR?=	MmDMNVk6QTZ{N{K=
MDA-MB-415	NXzndoFsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MoDyglUh\|ryP	Ml7iSG1UVw>?	MmfMTWM2OD53LkCwJO69VQ>?	M2DKXVE6QTl4Mkey
DLD-1	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYP+OUDPxE1?	MnK3SG1UVw>?	Mn\CTWM2OD1yLkmwPUDPxE1?	NI\SXo8yQTl7NkK3Ni=>
H2595	NHixcmdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MU\+OUDPxE1?	MYHEUXNQ	NFLYbXBKSzVyPUSuOFc2KM7:TR?=	MofONVk6QTZ{N{K=
MDA-MB-435S	M2PHU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnO4glUh\|ryP	MoWzSG1UVw>?	M4H2fWlEPTB;MT64Olkh\|ryP	M1TIfFE6QTl4Mkey
HCT15	NVPMZXdMT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX\+OUDPxE1?	MYXEUXNQ	NVzjS2RqUUN3ME6xMlAxKM7:TR?=	NVnLZ2xvOTl7OU[yO\|I>
SK-Hep1	M2[yemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MWP+OUDPxE1?	MYLEUXNQ	NFrJR\|FKSzVyPUCuNVQ3KM7:TR?=	MYmxPVk6PjJ5Mh?=
MDA-MB-436	M4OzdGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlS1glUh\|ryP	MX\EUXNQ	Mlr6TWM2OD13LkWwNkDPxE1?	NEDtb5oyQTl7NkK3Ni=>
KM12C	NVjqXW15T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2j5eJ42KM7:TR?=	MlX6SG1UVw>?	M1HkXGlEPTB;MD6wOVQh\|ryP	M12yW\|E6QTl4Mkey
HEPG2	MlrvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWj+OUDPxE1?	MY\EUXNQ	M4jQeWlEPTB;MD6wNlUh\|ryP	MUCxPVk6PjJ5Mh?=
MDA-MB-453	NVnzd4N2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2n5b542KM7:TR?=	NEXvZYRFVVOR	Ml\rTWM2OD1zLki2PUDPxE1?	Mn7KNVk6QTZ{N{K=
KM12SM	NYHXN2RYT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkTMglUh\|ryP	MkXRSG1UVw>?	M2TybWlEPTB;MD6wOVkh\|ryP	MVWxPVk6PjJ5Mh?=
1483	M4\USmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NV\SfpIzhjVizszN	MYrEUXNQ	Ml3pTWM2OD1{LkG5JO69VQ>?	MWSxPVk6PjJ5Mh?=
Hs578t	MlfnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWP2N3N7hjVizszN	NES2bIxFVVOR	MnmyTWM2OD1zLkK4O{DPxE1?	NVuzcYdMOTl7OU[yO\|I>
LS180	MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NV\ESlJRhjVizszN	M3;Kc2ROW09?	NVX6bpNYUUN3ME2wMlY6PiEQvF2=	MkD5NVk6QTZ{N{K=
FaDu	MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4LuUJ42KM7:TR?=	MWTEUXNQ	M3zaPGlEPTB;MT6yO{DPxE1?	NUnieVRyOTl7OU[yO\|I>
ZR-75-1	NXvUbpk1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MofPglUh\|ryP	NYn0R2w{TE2VTx?=	MXzJR\|UxRTJwMEi0JO69VQ>?	M4jtbVE6QTl4Mkey
LS513	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlzFglUh\|ryP	NVHPVlQxTE2VTx?=	NI\aO4hKSzVyPUCuNVM2KM7:TR?=	NEDBdZIyQTl7NkK3Ni=>
Detroit.562	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2nTXp42KM7:TR?=	NGjOUGVFVVOR	NXvKU4pvUUN3ME2xMlE1KM7:TR?=	M3qzcVE6QTl4Mkey
ZR-75-30	MljpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlfjglUh\|ryP	NGS1U3pFVVOR	NUHtc4J4UUN3ME61MlAxKM7:TR?=	NVzKcIdROTl7OU[yO\|I>
RKO-PM	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXXMdmhkhjVizszN	NEP2VphFVVOR	M2PzUmlEPTB;MD6yN\|Ih\|ryP	NE\X[WwyQTl7NkK3Ni=>
Cal.27	M1LTU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHTObmt,PSEQvF2=	MoD5SG1UVw>?	Moj0TWM2OD1{IN88US=>	NGTGeoUyQTl7NkK3Ni=>
KPL4	NFLWfGNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4HT[Z42KM7:TR?=	MlnnSG1UVw>?	M4Dlc2lEPTB;MT6yOVIh\|ryP	NFvFOXYyQTl7NkK3Ni=>
PKO-RM13	M1TwPWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NG\qTnJ,PSEQvF2=	MoLRSG1UVw>?	MoDiTWM2OD1yLkSyOUDPxE1?	MnvJNVk6QTZ{N{K=
HS.53.T	M3H1R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYnKT\|NRhjVizszN	NHzwPZlFVVOR	Ml;oTWM2OD1yLke5JO69VQ>?	NE\wTGkyQTl7NkK3Ni=>
EMT6	NH3Ue3RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2HJXJ42KM7:TR?=	MVvEUXNQ	NFTHSJBKSzVyPUCuPFA3KM7:TR?=	MVuxPVk6PjJ5Mh?=
SNU-C1	M4PZ[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1XPPJ42KM7:TR?=	NXH0XYhqTE2VTx?=	NX;EU\|BtUUN3ME2wMlAxPyEQvF2=	NELzXVEyQTl7NkK3Ni=>
SQCCY1	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYn6TWx[hjVizszN	NF\SSW9FVVOR	MnzlTWM2OD1yLke5JO69VQ>?	NHzodZMyQTl7NkK3Ni=>
SW480	NHfXUnlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYn+OUDPxE1?	MnX0SG1UVw>?	NFfkWG5KSzVyPUCuNFM4KM7:TR?=	M1zCZlE6QTl4Mkey
SCC9	M2HONmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYL+OUDPxE1?	NXvQPWFKTE2VTx?=	MnrZTWM2OD1yLke1JO69VQ>?	MoeyNVk6QTZ{N{K=
SK-LMS-1	NEDzdFVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWD+OUDPxE1?	MULEUXNQ	MoTGTWM2OD1yLk[4O{DPxE1?	MkC1NVk6QTZ{N{K=
SCC25	Mn7TS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmjvglUh\|ryP	NVXsXJFQTE2VTx?=	MlPsTWM2OD1yLk[4JO69VQ>?	M3OwbVE6QTl4Mkey
U87	Mon2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MonWglUh\|ryP	MY\EUXNQ	MkDwTWM2OD1yLkm1JO69VQ>?	MYKxPVk6PjJ5Mh?=
SCC15	NGLRWIxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYT+OUDPxE1?	MVnEUXNQ	MV7JR\|UxRTBwNkeg{txO	MXOxPVk6PjJ5Mh?=
T98G	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWH+OUDPxE1?	MULEUXNQ	M3TGNmlEPTB;MT6yNVgh\|ryP	MWWxPVk6PjJ5Mh?=
SCC4	MnjFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoriglUh\|ryP	NIDrOYhFVVOR	M1;D[GlEPTB;MD62N{DPxE1?	M13wUVE6QTl4Mkey
U118	MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NHPJcol,PSEQvF2=	NHjhW4lFVVOR	M3XOdmlEPTB;MT62NVgh\|ryP	M1THbVE6QTl4Mkey
TU167	MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1\iUJ42KM7:TR?=	NWT3fFFFTE2VTx?=	M4jPNGlEPTB;ND61NkDPxE1?	NX3ER2lrOTl7OU[yO\|I>
NCI-H727	M4HCZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mn;hglEx6oDMzszN	MWnEUXNQ	NUfUSm5iUUN3ME20Nlghdk1?	MlPvNlA{QDV5NEe=
NCI-H720	MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2HUSJ4yOOLCit88US=>	M4\BOmROW09?	MkjDTWM2OD1{Lkig{txO	NWXscJAzOjB\|OEW3OFc>
NCI-H835	NVrWdZh7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWO5XFBShjFy4pEK{txO	MU\EUXNQ	M1;zc2lEPTB;MTFOwG0>	M1n4OFIxOzh3N{S3
NCI-H727	Mk\TT4lv[XOnIHHzd4F6	MV;+NVDjiIsQvF2=	MnvvSG1UVw>?	M4XZcYlvcGmkaYTzJINwdnO2aYT1eIl3\SCLR1[xVkBifXSxcHjvd5Bpd3K7bHH0bY9v	MVqyNFM5PTd2Nx?=
RD	NGr0[olIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1zpbp4yOOLCit88US=>		NVnINYtHUUN3ME2xMlEzKML3TR?=	NEfsW3YzOTJ7OEe0OS=>
Rh41	M2rRNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFPibpN,OTEkgJtOwG0>		MorRTWM2OD1yLkC3JOK2VQ>?	NVWwUGtsOjF{OUi3OFU>
Rh18	NFjmcFFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWL+NVDjiIsQvF2=		MnHvTWM2OD12Lkm2JOK2VQ>?	NX;FdWo4OjF{OUi3OFU>
Rh30	M2S3PGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mkj3glEx6oDMzszN		NXfiSZhUUUN3ME2wMlE6KML3TR?=	NWDKUJZKOjF{OUi3OFU>
BT-12	MkXRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mkf1glEx6oDMzszN		NEixfnZKSzVyPUCuO\|ghyrWP	MXuyNVI6QDd2NR?=
CHLA-266	MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXLVVHRXhjFy4pEK{txO		NET2epFKSzVyPUCuPFkhyrWP	M{D2clIyOjl6N{S1
TC-71	M4LBWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYr+NVDjiIsQvF2=		MWDJR\|UxRTBwMUGgxtVO	Mmf4NlEzQTh5NEW=
CHLA-9	M3jp[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXXCR2M4hjFy4pEK{txO		MW\JR\|UxRTBwMUKgxtVO	NYHsUGhCOjF{OUi3OFU>
CHLA-10	MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEHVfWp,OTEkgJtOwG0>		M2O3XWlEPTB;MD62NkDDvU1?	M33VTVIyOjl6N{S1
CHLA-258	NWjjUJBkT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1;W[Z4yOOLCit88US=>		NXzQNmZQUUN3ME2wMlI4KML3TR?=	NFvLb4gzOTJ7OEe0OS=>
GBM2	NV\5V3VHT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MlfKglEx6oDMzszN		MlLDTWM2OD1zLkS3JOK2VQ>?	MkjJNlEzQTh5NEW=
NB-1643	MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUX+NVDjiIsQvF2=		M1fFXGlEPTB;MD6xNkDDvU1?	NH20cG4zOTJ7OEe0OS=>
NB-EBc1	MlfJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mnn3glEx6oDMzszN		M2\PRmlEPTB;MD6zOUDDvU1?	MYCyNVI6QDd2NR?=
CHLA-90	NUDyPJYyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEfuVnZ,OTEkgJtOwG0>		Mln4TWM2OD1yLke3JOK2VQ>?	MnjCNlEzQTh5NEW=
CHLA-136	NUjPZXplT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MoW3glEx6oDMzszN		NWX5XItOUUN3ME2wMlUzKML3TR?=	Mn23NlEzQTh5NEW=
NALM-6	MlzsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoHLglEx6oDMzszN		Mnu4TWM2OD1yLkS5JOK2VQ>?	Mn7pNlEzQTh5NEW=
COG-LL-317	NH3L[pJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Ml\3glEx6oDMzszN		MYTJR\|UxRTFwM{igxtVO	MYGyNVI6QDd2NR?=
RS4;11	Mn7NS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUj0XIozhjFy4pEK{txO		MofDTWM2OD1yLkO4JOK2VQ>?	NWrld\|VROjF{OUi3OFU>
MOLT-4	M2rL[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWf3TWtRhjFy4pEK{txO		M{TlV2lEPTB;MD61N{DDvU1?	NGLVT2QzOTJ7OEe0OS=>
CCRF-CEM	Mn3CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHrBNId,OTEkgJtOwG0>		MWTJR\|UxRTFwMUOgxtVO	MlzzNlEzQTh5NEW=
Kasumi-1	MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2L2ZZ4yOOLCit88US=>		NFm1O2lKSzVyPUGuNkDDvU1?	M{fkb\|IyOjl6N{S1
Karpas-299	Mn7TS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnOxglEx6oDMzszN		NYC3Zms5UUN3ME2xMlY1KML3TR?=	MXmyNVI6QDd2NR?=
Ramos-RA1	NXzxZ2hkT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkTRglEx6oDMzszN		MoHtTWM2OD1zLkOxJOK2VQ>?	MVKyNVI6QDd2NR?=
Rh30	NF3HbVBHfW6ldHnvckBie3OjeR?=			NF;pW5ZqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:\|cHjvdplt[XSrb36=	M37TU\|I2QTJ3M{e4
Rh41	M3jsOmZ2dmO2aX;uJIF{e2G7			NWTwR45ucW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u	MXSyOVkzPTN5OB?=
RD	MVLGeY5kfGmxbjDhd5NigQ>?			MnLFbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w	Ml;DNlU6OjV\|N{i=
A549	MVzLbY5ie2ViYYPzZZk>	M2rR[lAvPeLCit88US=>	MYjEUXNQ	M2DlfYlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v	NWDp[nVSOjZ7Mki1O\|g>
NCI-H358	M3zJdWtqdmG\|ZTDhd5NigQ>?	M3vZXVAvPeLCit88US=>	MWXEUXNQ	NX7ofXFZcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25?	Mlv0NlY6Ojh3N{i=
A549	MlT6SpVv[3Srb36gZZN{[Xl?	NYT1[HZYOC534pEK{txO	Mm\lSG1UVw>?	M1zyXoNifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt?	MkLGNlY6Ojh3N{i=
NCI-H358	M3zhfmZ2dmO2aX;uJIF{e2G7	MmLZNE426oDMzszN	MnvNSG1UVw>?	NFyyOGtk[XW\|ZYOgZUBkd26ldYLy[Y51KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGNVDDhcoQhTVKN	M2H2TFI3QTJ6NUe4
A549	NF7STXlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGm3emF,OTEkgJtOwG0>	NY\r[oZQTE2VTx?=	NXTRTm84UUN3ME2wMlc3KM7:TR?=	M3rkTVI3QTJ6NUe4
NCI-H358	NXfKVFZ5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHrGdJp,OTEkgJtOwG0>	NUHYS2J[TE2VTx?=	NHrwdGhKSzVyPUGuNFkh\|ryP	MYqyOlkzQDV5OB?=
A549	NFf5foVCeG:ydH;zbZMh[XO\|YYm=	NELH[5kxNjYkgJtOwG0>	MoDqSG1UVw>?	MknEbY5lfWOnczDBdI9xfG:\|aYO=	Ml2yNlY6Ojh3N{i=
NCI-H358	NH\mOoxCeG:ydH;zbZMh[XO\|YYm=	NF70[W0xNjYkgJtOwG0>	M2i2e2ROW09?	MWjpcoR2[2W\|IFHwc5B1d3Orcx?=	NGnnOHMzPjl{OEW3PC=>
A549	NX;GO3JWTnWwY4Tpc44h[XO\|YYm=	NGiyW\|MxNjYkgJtOwG0>	M3PYVGROW09?	MkjLdoVlfWOnczD3c5Vv\CClbH;zeZJm	MVyyOlkzQDV5OB?=
NCI-H358	NHW4b3lHfW6ldHnvckBie3OjeR?=	Mnr1NE426oDMzszN	M3XE[2ROW09?	NV;LZ4pXemWmdXPld{B4d3WwZDDjcI9{fXKn	NX76WmQ6OjZ7Mki1O\|g>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; PubMed: 26136493 Neuro Oncol (C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.	26136493
Growth inhibition assay	Cell viability; PubMed: 30754629 Molecules Response of SK-CO-1 to various drugs and drug combinations.	30754629

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	- Collapse Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	- Collapse Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol) Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324|Bemcentinib) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 14 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 14 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)